Literature DB >> 27746646

A Case of Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans Syndrome; Increase in Proliferating Cell Nuclear Antigen and Decrease in Loricrin in Acanthosis Nigricans.

Kanami Saito1, Hisae Ando2, Koro Goto2, Tetsuya Kakuma2, Yasushi Kawano3, Hisashi Narahara3, Yutaka Hatano1, Sakuhei Fujiwara1.   

Abstract

Entities:  

Year:  2016        PMID: 27746646      PMCID: PMC5064196          DOI: 10.5021/ad.2016.28.5.637

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


× No keyword cloud information.
Dear Editor: HAIR-AN syndrome is an unusual multisystem disorder that consists of hyperandrogenism (HA), insulin resistance (IR), and acanthosis nigricans (AN)1. HAIR-AN syndrome is known to develop by various causes including underlying malignancy, systemic disease, obesity, and drug2. For the diagnosis of HAIR-AN syndrome, a variety of comprehensive targeted laboratory evaluations are necessary1 as described here. A 31-year-old woman who had been obese since a schoolgirl presented us with a variety of hyperandrogenic features such as hypertrichosis (Fig. 1A, B) and amenorrhea. In addition, she presented hyperpigmented, velvety patches on her axilla (Fig. 1C), the nape of her neck (Fig. 1D) and the dorsal aspect of her phalangeal joints (Fig. 1E). She was also a nullipara. Her height and body weight was 155 cm and 100 kg, respectively. Though serum levels of follicle-stimulating hormone, luteinizing hormone, prolactin, adrenocorticotropic hormone (ACTH), cortisol and thyroid-stimulating hormone were normal, those of testosterone (82.6 ng/dl; normal range, 10~60 ng/dl), dehydroepiandrosterone sulfate (404 µg/dl; normal range, 23~266 µg/dl) and 17α-hydroxyprogesterone (7.8 ng/ml; normal range, 0.2~4.5 ng/ml) were elevated. Serum electrolyte panel was normal. Computed tomography and magnetic resonance image pointed out neither tumors of ovarian and adrenal gland nor adrenal hyperplasia. Results of ACTH stimulation test and dexamethasone suppression test were normal. Taken together, we could exclude Cushing's syndrome, congenital adrenal hyperplasia, polycystic ovary syndrome and virilizing tumor. HbA1c was 6.3% (normal range, <5.8%). Serum Insulin level was elevated (27.1 pmol/l; normal range, 5~10 µU/ml) and 75 g oral glucose tolerance test showed excessive secretion of insulin, indicating IR. Antinuclear antibodies, anti-insulin antibody, and anti-insulin receptor antibody were negative. Histological examination on her axilla revealed epidermal papillomatosis and acanthosis with orthohyperkeratosis, and no significant inflammatory infiltrate (Fig. 1F). Finally, we diagnosed her with HAIR-AN syndrome. She has no familial histories of HAIR-AN syndrome.
Fig. 1

Hypertrichosis on her face (A: eyebrows, B: chin) and hyperpigmented, velvety patches on her axilla (C), the nape of her neck (D) and the dorsal aspect of her phalangeal joints (E). Histological examination revealed epidermal papillomatosis and acanthosis with orthohyperkeratosis, and no significant inflammatory infiltrate (F). (F) H&E, ×40.

An immunohistochemistry on her axilla revealed the conspicuous increase in proliferating cell nuclear antigen-positive cells, especially in basal layer (Fig. 2B) and the reduced and abnormally expanding expression of loricrin in granular and spinous layer (Fig. 2D). An immunohistochenistry on the axilla of an age-matched female healthy volunteer (Fig. 2A, C) was performed under approval of the Ethics Committee of Oita University.
Fig. 2

Immunohistochemical staining on axilla of the patient revealed the conspicuous increase in proliferating cell nuclear antigen (PCNA)-positive cells, especially in basal layer and the reduced and abnormally expanding expression of loricrin in granular and upper spinous layers. (A) PCNA in a healthy volunteer, (B) PCNA in the patient. (C) loricrin in a healthy volunteer, (D) loricrin in the patient. A~D: ×100.

The patients with HAIR-AN syndrome would have an increased risk of hyperlipidemia and secondary coronary artery disease. Considering that patients with HAIR-AN syndrome often present with cosmetic concerns such as virilization and AN, dermatologists must maintain a high index of suspicion for HAIR-AN syndrome. It has been hypothesized that AN is caused by long-term exposure of the keratinocytes to excessive insulin via binding of insulin-like growth factor receptors (IGF-R) with resultant hyperplasia of the skin3. In fact, insulin-like growth factor accelerates keratinocyte proliferation4. Expression of loricrin was enhanced in IGF-1R-deficient murine keratinocyte5. However, in vivo expression of proliferation and/or differentiation-related molecules on AN has not been reported. The present results of the immunohistochmistry support those in vitro studies and clearly demonstrate that hyperproliferation and abnormal differentiation of epidermis took place under insulin resistant condition in vivo, presumably via IGF-R signaling.
  5 in total

Review 1.  Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans.

Authors:  P D Cruz; J A Hud
Journal:  J Invest Dermatol       Date:  1992-06       Impact factor: 8.551

2.  HAIR-AN syndrome: a multisystem challenge.

Authors:  K B Elmer; R M George
Journal:  Am Fam Physician       Date:  2001-06-15       Impact factor: 3.292

3.  Familial acanthosis nigricans. A longitudinal study.

Authors:  C I Friedman; S Richards; M H Kim
Journal:  J Reprod Med       Date:  1987-07       Impact factor: 0.142

4.  Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor.

Authors:  J F Krane; D P Murphy; D M Carter; J G Krueger
Journal:  J Invest Dermatol       Date:  1991-04       Impact factor: 8.551

5.  Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.

Authors:  Marianna Sadagurski; Shoshana Yakar; Galina Weingarten; Martin Holzenberger; Christopher J Rhodes; Dirk Breitkreutz; Derek Leroith; Efrat Wertheimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.